Publication date: Jul 30, 2026
Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults [≥]65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).
| Concepts | Keywords |
|---|---|
| Adapted | |
| Adults | |
| Bnt162b2 | |
| California | |
| Claims | |
| Covid | |
| Immunization | |
| Index | |
| Louisiana | |
| Lp | |
| Preprint | |
| Registry | |
| Vaccine | |
| Year | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | MS2 |
| disease | MESH | PFE |
| disease | MESH | emergency |
| disease | MESH | ICD |
| disease | MESH | SMD |
| disease | MESH | influenza |
| disease | MESH | plan |
| disease | MESH | included |
| disease | MESH | diabetes mellitus |
| disease | MESH | obesity |
Download Document
(Visited 3 times, 1 visits today)